Past Investments

ALIGN TECHNOLOGY, INC.

Align Technology designs, manufactures and markets the Invisalign System, a novel method for treating malocclusion, or the misalignment of teeth.  The System corrects malocclusion using a series of clear, removable appliances that gently move teeth to a desired final position.  Align Technology went public in 2001.


AMIRA MEDICAL, INC.

Amira Medical developed the AtLast integrated blood glucose measurement system that featured painless, convenient alternate site blood collection and glucose measurement. Amira was acquired by Roche Diagnostics in 2001.  


ARRINEX, INC.

Arrinex has developed a disruptive cryotherapy technology for treating chronic nasal allergy symptoms: congestion and drainage.  The Arrinex technology replicates surgical results with a non-invasive 15-minute procedure that is performed in the ENT office under local or topical anesthesia. In patients treated with the Arrinex technology, the procedure has been safe and the long term results satisfying to patients and physicians. Arrinex was acquired by Stryker in February 2019.


BREATHE TECHNOLOGIES, INC.

Breathe Technologies is developing novel COPD therapy devices that are designed to significantly improve existing ventilation and supplemental oxygen therapy products, and provide dramatic quality of life benefits for COPD patients that require assisted ventilation or oxygen therapy.   Breathe was acquired by HillRom in 2019.


CARDIAC PATHWAYS CORPORATION

Cardiac Pathways Corporation developed minimally invasive, clinically superior systems to diagnose and cure cardiac tachyarrhythmias, a serious medical condition characterized by a rapid heart rate.  The Company went public in 1996 and was acquired by Boston Scientific in 2001.


CHESTNUT MEDICAL, INC.

Chestnut Medical develops novel devices for interventional neuroradiology procedures.  The Company’s flagship product, the Pipeline aneurysm device, is a fine mesh tubular device that is used to isolate an aneurysm from blood flow without the need for coils.   In June 2009 Chestnut Medical was acquired by ev3.


C2 THERAPEUTICS

C2 Therapeutics has developed novel disposable devices to treat Barrett’s Esophagus, an early precursor to esophageal cancer.  C2 Therapeutics’ CryoBallon Ablation System consists of a disposable hand-held controller, a conformable clear balloon and is delivered through a bronchoscope.   The CryoBallon Ablation System is superior to existing RF balloon ablations as it does not require a sizing procedure, any capital equipment, and benefits from an easier and quicker procedure. In January 2017 C2 Therapeutics was acquired by Hoya Pentax.


CV INGENUITY, INC.

CV Ingenuity developed drug eluting balloon and coating technology for use in peripheral vascular interventional procedures to reduce the rate of restenosis.  CV Ingenuity was acquired by Covidien in December 2012.


ENTERIC MEDICAL TECHNOLOGIES, INC.

Enteric Medical Technologies designs, develops, and plans to market novel minimally invasive implant systems for the treatment of gastroesophageal reflux disease (GERD).  Enteric Medical was acquired by Boston Scientific in 2002.

 

FOX HOLLOW TECHNOLOGIES, INC.

Fox Hollow Technologies develops, designs and plans to market a novel percutaneous atherectomy device for optimal debulking of occluded coronary arteries.    The Company went public in 2001 and was acquired by ev3 in 2007.


INTUITIVE SURGICAL, INC.

Intuitive Surgical was founded in 1995 to create innovative, robotic-assisted systems that help empower doctors and hospitals to make surgery less invasive than an open approach. da Vinci became one of the first robotic-assisted systems cleared by the FDA for general laparoscopic surgery and Intuitive is the leader in robotic surgery systems worldwide. The Company went public in 2000. 


MEDINA MEDICAL INC.

Medina Medical developed an revolutionary neurovascular mesh coil implant to address the unmet need of treating intricate bifurcation and wide necked giant aneurysms, which represent 60% of all brain aneurysm cases today.  The Medina device represents a true next generation, single-device solution for aneurysms, which can be deployed rapidly with no need for balloon protection or other device to protect from downstream coil loss. The Company was acquired by Medtronic in 2015.

 

MEDIVANCE, INC.     

Medivance develops, manufactures and markets the noninvasive Arctic Sun patient temperature management system for hypothermia treatment in neuro applications such as stroke and fever control, and in heart attack and cardiac arrest patients.  Medivance was acquired by CR Bard in 2011.

 

MOMELAN TECHNOLOGIES, INC.

MoMelan Technologies has developed the ‘Epidermal Expansion System (EES),’ a point-of-care, compact medical device that will provide physicians with the first viable approach to perform standardized epidermal expansion and skin grafting in less than one hour. MoMelan’s technology provides the ability to significantly expand (up to 100x) the size of an autologous epidermal skin graft with high reliability and repeatability.  Momelan was acquired by KCI in 2013.


NATUS MEDICAL INC.

Natus develops, manufactures and markets proprietary electronic medical instruments and related disposables for the perinatal sector of the hospital equipment market, including obstetrics, neonatology and pediatrics. Natus went public in 2001.

 

OMNICELL TECHNOLOGIES, INC.

OmniCell Technologies designs, manufactures, markets and services automated point‑of‑use supply stations and software that improves the management and control of supplies in hospitals.   OmniCell went public in 2001.

 

PERCLOSE, INC.

Perclose, Inc. designs, manufactures and markets proprietary suturing devices to close arterial access puncture sites following vascular catheterization procedures.   The Company went public in 1995 and was acquired by Abbott in 1999.


PHORMAX, INC.

Phormax developed low cost computed radiography (CR) instruments based on their patented laser scanning technology.  The Company merged with Alara Medical in the second quarter of 2002.   


PHYSIOMETRIX, INC.

Physiometrix designs, manufactures and markets proprietary diagnosis and monitoring products for the neurophysiology market.   The Company went public in 1996.


RETROVASCULAR, INC.

RetroVascular is developing a family of tools to allow the interventional cardiologist to treat chronic total occlusions, or CTOs, easily and rapidly, using a retrograde approach.  Current research involves the use of novel plasma pulse technology in catheters to create channels through CTOs quickly and safely.  RetroVascular was acquired by Asahi Intecc Co., Ltd. in 2018. 


RITA MEDICAL SYSTEMS, INC.

RITA Medical Systems markets novel, minimally invasive surgical ablation systems for the treatment of solid organ tumors.  RITA’s initial products will target primary and metastatic tumors of the liver and other organs, with newer devices planned for bone cancer.  RITA Medical went public in 2000.

 

SALIENT SURGICAL, INC.

Salient Surgical, formerly TissueLink,  designs, develops and markets disposable surgical products to cut, shrink, and seal tissue using RF energy and saline as a ‘liquid electrode’.   Main applications are in liver cancer and orthopedic procedures.  Salient was acquired by Medtronic in 2011.

 

SEVIDENT, INC.

Sevident is developing assays built on their patented molecular net technology that can allow extremely low limits of detection and fast test results.  The technology does not require the presence of whole, metabolically active bacteria in a given sample, because it also contains capture molecules to detect protein signatures and the bits and pieces of bacteria, thereby increasing sensitivity. Sevident's molecular net platform is highly flexible, with rapid product development cycles -- a new assay can move from design to working prototype in less than a month, due to the technology's simple design and straightforward manufacturing processes. Sevident was acquired by Sienna Cancer Diagnostics in April 2019.


ULTRACISION, INC.

UltraCision designs, develops, manufactures, and markets advanced minimally invasive surgical instruments based on its proprietary core technologies in ultrasound energy and harmonic motion.  The Company was acquired by Johnson & Johnson in 1995.   


VIDAMED, INC.

VidaMed, Inc. designs, develops, manufactures and markets cost-effective and clinically efficacious devices for the treatment of significant urologic conditions.  The Company went public in 1995 and was acquired by Medtronic in 2001.


545 Middlefield Road       Suite 205     Menlo Park   California  94025                           tel /fax 650 322 3475